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estimated for the stomach and stomach wall with endpoints 
of ulceration and gastric bleeding respectively (6) & (7).  
Results: The stomach wall model showed larger values of 
NTCP than the whole stomach. There was a mean increase of 
5.93% (-0.42, 18.71%) in NTCP from the 50Gy3D to the 60GyRA 
plans and a mean increase of 8.15% (-0.42, 19.79%) in NTCP 
from the 50GyRA to the 60GyRA plans. When the NTCP 
modelling is restricted to that outside PTV2, there was a 
mean decrease of 0.92% (-4.70, 1.00%) in NTCP from the 
50Gy3D to the 60GyRA plans, and a mean increase of 2.25% (-
0.42, 6.91%) in NTCP from the 50GyRA to the 60GyRA plans. 
There was a strong correlation between the NTCP value and 
the Stomach Wall/PTV1 overlap volume for all treatment 
plans (Pearson’s R=0.80, 0.77 and 0.77 for the 60GyRA, 50GyRA 
and 50Gy3D plans respectively). There was also a strong 
correlation between the NTCP value and the Stomach 
Wall/PTV2 overlap volume for the 60GyRA plan (R= 0.82). 
Conclusions: Radiobiological modelling suggests that 
increasing the prescribed dose to 60Gy may be associated 
with a significantly increased risk of toxicity to the stomach. 
The results of this study also suggest that the maximum 
prescribed dose safely achievable for each patient in the 
future may be dependent on the volume of the stomach 
within the treatment volume. It is recommended that 
stomach toxicity be closely monitored prospectively when 
treating patients with lower oesophageal tumours in the 
forthcoming SCOPE 2 trial. 
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Purpose/Objective: The Italian Association of Medical Physics 
(AIFM) instituted in 2012 a working group dedicated to the 
Stereotactic ablative body radiotherapy (SABR). The aim of 
this work is to identify possible criticisms in approaching 
multicentric clinical trial for lung SABR, comparing, from a 
radiobiologic and dosimetric point of view, the plans 
obtained with different treatment planning systems, 
techniques and planners. 
Materials and Methods: Five CT series from a database of 
patients treated with RT on lung were sent to the 
participants. Dose prescription was 54 Gy in 3 fractions of 18 
Gy each to planning target volume (PTV). Each participant 
was asked to prescribe dose in conformity to its experience 
(i.e. 100%, 80%, mean dose) to stress the individuality of 
every center. For all plans were calculated: the PTV gEUD 
(generalized equivalent uniform dose), the MLD (mean lung 
dose) equivalent to 2 Gy for ipsilateral lung minus CTV and 
OAR (organ at risk) maximum dose. The dosimetric data and 
the parameters related to each center were analyzed 
including : expertise, equipment, size of leaves, TPS, 
radiation technique, and energy of radiation. Furthermore, a 
performance index was defined for each dosimetric 
parameter to compare plans with diferences in terms of the 
PTV gEUD. For example the performance index regarding 
MLDeq2Gy is defined a PI =  
(MLDeq2Gy/gEUD)Reference/(MLDeq2Gy/ gEUD)center. and 
the Reference value belongs to a center with mean 
performances. 
Results: Twenty-six centers with 3D-Conformal RT, IMRT, 
VMAT (Linac 88%), CyberKnife (4%) and Tomotherapy (8%) 
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joined this inter-comparison. Almost every region of Italy was 
represented. In figure 1, the distribution of the PTV gEUD and 
of the MLDeq2Gy PI are shown. The dot line is the minimum 
PI required value; the spread of the data intra-institution and 
inter-institution is visible. The PI related to the rib max dose 
shows a significant correlation (p=0.01) with the use of 
CyberKnife versus Linac or Tomo. Almost all centers have 
values above the minimum required index but all of them, 
except for CyberKnife, show performances below the 
reference one, indicating a weak consideration of this 
constraint. Otherwise, for the PI of spinal cord max dose, all 
center are above the dot line. Any correlation was found 
between performances and the participants expertise or for 
other technical parameters. 
 
 
Figure 1: distribution of gEUD among the centres and of 
MLDeq2Gy performance index. The dot line is the minimum 
required value. 
 
Conclusions: A notable inter-institutional difference in terms 
of gEUD and general planning strategies was found. For a 
multi-institutional study perspective, detailed dose 
specification and planning strategies based on collaboration 
and discussion are mandatory. 
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Purpose/Objective: 4DCT and CBCT imaging in radiotherapy 
delivers a small priming dose, which is ignored in treatment 
planning, despite evidence that the size and sequence of 
partial fractions affects cell survival1,2. The delay between 
imaging and treatment may be minutes or days for CBCT and 
4DCT respectively. There is a trend towards increasing use of 
these imaging modalities as they enable more accurate 
delivery of therapeutic dose. The biological effect of an 
imaging partial fraction in addition to the therapeutic dose 
on cell survival is uncertain. We report here on the effect of 
an imaging dose prior to a therapeutic dose on cell survival in 
two human cancer cell lines and one normal human cell line. 
The effects are examined for current typical imaging dose 
levels and a projection is made of the effects on cell survival 
of an increase in the imaging dose. 
Materials and Methods: In-vitro clonogenic assays were used 
to obtain experimental data for non-small cell lung cancer 
(NCI-H460), melanoma (MM576) and a normal (HUVEC) cell 
lines. The 4DCT was performed on a Toshiba Aquilon CT with 
a Varian RPM motion management system and the CBCT on a 
6MV proton beam from a Varian Novalis linac with a kV-cone 
beam system. The therapeutic dose D2 was delivered after 
time t using the Varian Novalis. An expression for cell survival 
S was derived using the Lea-Catcheside formalism, with and 
without the imaging dose D1. The effect on cell survival of 
increasing the imaging dose to a projected 10, 20 and 50 cGy 
was modelled. 
Results: For the two human cancer cell lines considered in 
this study, D1 (measured to be 0, 0.60cGy [CBCT] or 14.0 cGy 
[4DCT]) given prior to a D2 (0, 2 or 4 Gy), has no measurable 
effect on cell survival, irrespective of the time delay. The 
theoretical analysis confirmed the experimental findings for 
these imaging doses, that an additional partial fraction dose 
from CBCT or 4DCT is not likely to affect tumour control 
significantly as the cell survival was predicted to decrease by 
2-3% for 4DCT. However, if the imaging dose is increased to 
20 and 50 cGy, it is predicted the clonogenic survival would 
decrease by 6 and 15% respectively for the cancer cell lines. 
This decrease was predicted to be smaller for the normal cell 
line (4 and 6% for 20 and 50 cGy respectively). 
Conclusions: This study indicates that, at the current dose 
levels, it is not necessary to consider the imaging dose from 
4DCT or CBCT in the planning of radiotherapy treatment. 
However, if the imaging dose is increased then imaging dose 
may need to be included in treatment planning. 
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Purpose/Objective: While conventionally fractionated 
radiotherapy (CFRT) has proven ineffective in curing non-
small-cell lung cancer (NSCLC), promising results have been 
obtained with stereotactic body radiotherapy (SBRT) 
employing few high-dose fractions. Extreme 
hypofractionation might however compromise the treatment 
outcome in hypoxic tumours given the reduced possibility for 
reoxygention between fractions. An alternative approach 
